Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07593092 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Trial sites reduced: 9 → 4 locations · Start date changed from estimate of Jun 2026 to Jun 30, 2026v2 Show 2 more changesShow less
    • Trial sites reduced: 9 → 4 locations
    • Start date changed from estimate of Jun 2026 to Jun 30, 2026
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Xencor
10 trials monitored
See all monitored trials
Ovarian Cancer
1,245 trials monitored
See 80 trials at risk
The primary purpose of this study is to determine whether the combination of the investigational drug XmAb541 in combination with the investigational drug XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on participants' tumor outcomes.
Trial Details
NCT Number NCT07593092
Lead Sponsor Xencor, Inc.
Conditions Ovarian Cancer
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov